medpace holdings - MEDP
MEDP
Close Chg Chg %
326.09 15.73 4.82%
Pre-Market
341.82
+15.73 (4.82%)
Volume: 422.89K
Last Updated:
Nov 21, 2024, 4:00 PM EDT
Company Overview: medpace holdings - MEDP
MEDP Key Data
| Open $327.25 | Day Range 325.84 - 342.35 |
| 52 Week Range 268.80 - 459.77 | Market Cap $10.14B |
| Shares Outstanding 31.08M | Public Float 25.52M |
| Beta 1.37 | Rev. Per Employee N/A |
| P/E Ratio 28.55 | EPS $11.83 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 444.50K |
MEDP Performance
| 1 Week | 10.04% | ||
| 1 Month | 3.51% | ||
| 3 Months | -12.56% | ||
| 1 Year | 23.39% | ||
| 5 Years | 356.25% |
MEDP Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About medpace holdings - MEDP
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
MEDP At a Glance
Medpace Holdings, Inc.
5375 Medpace Way
Cincinnati, Ohio 45227
| Phone | 1-513-579-9911 | Revenue | 1.89B | |
| Industry | Miscellaneous Commercial Services | Net Income | 282.62M | |
| Sector | Commercial Services | 2023 Sales Growth | 29.168% | |
| Fiscal Year-end | 12 / 2024 | Employees | 5,900 | |
| View SEC Filings |
MEDP Valuation
| P/E Current | 28.55 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 34.535 |
| Price to Sales Ratio | 5.176 |
| Price to Book Ratio | 16.826 |
| Price to Cash Flow Ratio | 22.522 |
| Enterprise Value to EBITDA | 26.653 |
| Enterprise Value to Sales | 5.133 |
| Total Debt to Enterprise Value | 0.017 |
MEDP Efficiency
| Revenue/Employee | 319,634.237 |
| Income Per Employee | 47,901.525 |
| Receivables Turnover | 6.32 |
| Total Asset Turnover | 1.253 |
MEDP Liquidity
| Current Ratio | 0.642 |
| Quick Ratio | 0.642 |
| Cash Ratio | 0.265 |
MEDP Profitability
| Gross Margin | 26.417 |
| Operating Margin | 17.861 |
| Pretax Margin | 17.80 |
| Net Margin | 14.986 |
| Return on Assets | 18.783 |
| Return on Equity | 59.792 |
| Return on Total Capital | 39.066 |
| Return on Invested Capital | 46.092 |
MEDP Capital Structure
| Total Debt to Total Equity | 29.428 |
| Total Debt to Total Capital | 22.737 |
| Total Debt to Total Assets | 9.928 |
| Long-Term Debt to Equity | 25.427 |
| Long-Term Debt to Total Capital | 19.645 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Medpace Holdings - MEDP
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 925.92M | 1.14B | 1.46B | 1.89B | |
Sales Growth
| +7.54% | +23.38% | +27.80% | +29.17% | |
Cost of Goods Sold (COGS) incl D&A
| 666.73M | 835.34M | 1.05B | 1.39B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 33.45M | 37.41M | 40.36M | 26.33M | |
Depreciation
| 25.58M | 32.29M | 37.00M | 24.13M | |
Amortization of Intangibles
| 7.88M | 5.11M | 3.35M | 2.20M | |
COGS Growth
| +4.43% | +25.29% | +25.69% | +32.17% | |
Gross Income
| 259.20M | 307.04M | 410.10M | 498.18M | |
Gross Income Growth
| +16.49% | +18.46% | +33.57% | +21.48% | |
Gross Profit Margin
| +27.99% | +26.88% | +28.09% | +26.42% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 92.16M | 108.42M | 131.40M | 161.35M | |
Research & Development
| - | - | - | - | - |
Other SG&A
| 92.16M | 108.42M | 131.40M | 161.35M | |
SGA Growth
| -3.24% | +17.65% | +21.19% | +22.79% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| 167.04M | 198.62M | 278.70M | 336.82M | |
Non Operating Income/Expense
| 1.49M | 3.34M | 7.07M | (655.00K) | |
Non-Operating Interest Income
| - | - | - | 307.00K | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | 105.00K | 2.90M | 488.00K | |
Interest Expense Growth
| - | - | +2,666.67% | -83.20% | - |
Gross Interest Expense
| - | 105.00K | 2.90M | 488.00K | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 168.53M | 201.85M | 282.86M | 335.68M | |
Pretax Income Growth
| +35.01% | +19.77% | +40.13% | +18.67% | |
Pretax Margin
| +18.20% | +17.67% | +19.37% | +17.80% | |
Income Tax
| 23.15M | 20.00M | 37.49M | 52.87M | |
Income Tax - Current - Domestic
| 20.99M | 54.54M | 57.15M | 73.23M | |
Income Tax - Current - Foreign
| 1.59M | 2.58M | 3.33M | 4.62M | |
Income Tax - Deferred - Domestic
| 531.00K | (36.30M) | (23.00M) | (25.99M) | |
Income Tax - Deferred - Foreign
| 38.00K | (820.00K) | 13.00K | 1.01M | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| (459.00K) | (458.00K) | (157.00K) | (191.00K) | |
Consolidated Net Income
| 144.93M | 181.39M | 245.21M | 282.62M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 144.93M | 181.39M | 245.21M | 282.62M | |
Net Income Growth
| +44.69% | +25.16% | +35.18% | +15.26% | |
Net Margin Growth
| +15.65% | +15.88% | +16.80% | +14.99% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 144.93M | 181.39M | 245.21M | 282.62M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 144.93M | 181.39M | 245.21M | 282.62M | |
EPS (Basic)
| 4.0669 | 5.058 | 7.571 | 9.1992 | |
EPS (Basic) Growth
| +45.68% | +24.37% | +49.68% | +21.51% | |
Basic Shares Outstanding
| 35.63M | 35.86M | 32.39M | 30.72M | |
EPS (Diluted)
| 3.8434 | 4.8118 | 7.2826 | 8.876 | |
EPS (Diluted) Growth
| +44.19% | +25.20% | +51.35% | +21.88% | |
Diluted Shares Outstanding
| 37.71M | 37.70M | 33.67M | 31.84M | |
EBITDA
| 200.49M | 236.02M | 319.05M | 363.15M | |
EBITDA Growth
| +33.26% | +17.72% | +35.18% | +13.82% | |
EBITDA Margin
| +21.65% | +20.66% | +21.85% | +19.26% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 364.50 | |
| Number of Ratings | 11 | Current Quarters Estimate | 2.941 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 11.878 | |
| Last Quarter’s Earnings | 3.01 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 8.88 | Next Fiscal Year Estimate | 12.533 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 7 | 7 | 8 | 8 |
| Mean Estimate | 2.94 | 2.99 | 11.88 | 12.53 |
| High Estimates | 3.05 | 3.16 | 12.01 | 13.55 |
| Low Estimate | 2.80 | 2.92 | 11.71 | 12.18 |
| Coefficient of Variance | 3.32 | 3.02 | 0.95 | 3.54 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 4 | 6 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 5 | 6 | 4 |
| UNDERWEIGHT | 1 | 1 | 1 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Medpace Holdings - MEDP
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Medpace Holdings - MEDP
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 4, 2024 | Dani S. Zander Director | 824 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jul 3, 2024 | Brian T. Carley Director | 156 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 3, 2024 | Brian T. Carley Director | 21,752 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 3, 2024 | Cornelius P. McCarthy Director | 5,163 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 3, 2024 | Cornelius P. McCarthy Director | 124 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 3, 2024 | Robert O. Kraft Director | 520 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Jul 3, 2024 | Robert O. Kraft Director | 142 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 30, 2024 | August James Troendle CEO; Director | 660,351 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $395.22 per share | 260,983,922.22 |
| May 30, 2024 | August James Troendle CEO; Director | 654,656 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $395.49 per share | 258,909,901.44 |
| May 22, 2024 | Femida H. Gwadry-Sridhar Director | 953 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 22, 2024 | Ashley M. Keating Director | 953 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 22, 2024 | Fred B. Davenport Director | 953 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 20, 2024 | Susan E. Burwig Exec. VP, Operations | 15,181 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $403 per share | 6,117,943.00 |
| Mar 11, 2024 | August James Troendle | 4,733,019 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $408.71 per share | 1,934,432,195.49 |
| Mar 11, 2024 | Ashley M. Keating Director | 472 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $54.99 per share | 25,955.28 |
| Mar 11, 2024 | Ashley M. Keating Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 7, 2024 | Jesse J. Geiger President | 26,145 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $90.65 per share | 2,370,044.25 |
| Mar 7, 2024 | Jesse J. Geiger President | 3,824 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $403.03 per share | 1,541,186.72 |
| Mar 7, 2024 | Jesse J. Geiger President | 21,503 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $90.65 per share | 1,949,246.95 |
| Mar 7, 2024 | Jesse J. Geiger President | 17,679 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |